Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism (T4-T3)
Primary Purpose
Quality of Life, Depression
Status
Completed
Phase
Phase 4
Locations
Denmark
Study Type
Interventional
Intervention
Triiodothyronine
Sponsored by
About this trial
This is an interventional treatment trial for Quality of Life focused on measuring hypothyroidism, quality og life, depression
Eligibility Criteria
Inclusion Criteria:
- Hypothyroidism, S-TSH> 20 at diagnosis,Anti-TPO >300 Normal TSH (0,4-4,0) for 6 months.
Exclusion Criteria:
- <18 år
- >75 år
- pregnant women
- Thyroid cancer
- T3 treatment
- Post-partum thyroiditis
Sites / Locations
- Dept of endocrinology , Herlev Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Active Comparator
Arm Label
1
2
Arm Description
Usual T4 dose is given
20 microgram of T3 is given and 50 microgram of T4 is withdrawn
Outcomes
Primary Outcome Measures
Selv-rating scales: SF-36, SCL -90-R, BDI
Secondary Outcome Measures
BMI, bioimpedance
Full Information
NCT ID
NCT00531713
First Posted
September 18, 2007
Last Updated
September 18, 2007
Sponsor
Copenhagen University Hospital at Herlev
1. Study Identification
Unique Protocol Identification Number
NCT00531713
Brief Title
Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism
Acronym
T4-T3
Official Title
Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism,a Double Blind Randomized Cross-Over Study.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2007
Overall Recruitment Status
Completed
Study Start Date
April 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
March 2007 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Copenhagen University Hospital at Herlev
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To compare the effect of T4-T3 combination therapy versus T4 monotherapy in patients with autoimmune hypothyroidism, on stable T4-substitution therapy
Detailed Description
double blind randomized cross-over study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Quality of Life, Depression
Keywords
hypothyroidism, quality og life, depression
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
59 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
No Intervention
Arm Description
Usual T4 dose is given
Arm Title
2
Arm Type
Active Comparator
Arm Description
20 microgram of T3 is given and 50 microgram of T4 is withdrawn
Intervention Type
Drug
Intervention Name(s)
Triiodothyronine
Intervention Description
50 microgram of the usual T4 is withdrawn and the patients is given 20 microgram of T3
Primary Outcome Measure Information:
Title
Selv-rating scales: SF-36, SCL -90-R, BDI
Time Frame
3 month treating
Secondary Outcome Measure Information:
Title
BMI, bioimpedance
Time Frame
3 month treament
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Hypothyroidism, S-TSH> 20 at diagnosis,Anti-TPO >300 Normal TSH (0,4-4,0) for 6 months.
Exclusion Criteria:
<18 år
>75 år
pregnant women
Thyroid cancer
T3 treatment
Post-partum thyroiditis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Birte Nygaard
Organizational Affiliation
Herlev Trials
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dept of endocrinology , Herlev Hospital
City
Herlev
ZIP/Postal Code
dk-3650
Country
Denmark
12. IPD Sharing Statement
Learn more about this trial
Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism
We'll reach out to this number within 24 hrs